Telix and SHINE partner for Lutetium-177 Supply

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 11 February 2022. Telix announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for lutetium-177

Telix is pleased to announce a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for highly pure no-carrier-added (n.c.a.) lutetium-177 (177Lu), a therapeutic isotope used in Telix’s portfolio of molecularly targeted radiation (MTR) investigational products.

As Telix advances its late-stage clinical trials using the medical radioisotope 177Lu, it is building a global supplier network with proximity to major global markets, capable of consistently delivering high-quality, no-carrier-added 177Lu to patients. SHINE will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer), with particular focus on the U.S. market.

Dr. Gabriel Liberatore, Telix Group Chief Operating Officer said, “SHINE’s investment in high quality isotope production places them at the forefront of the radiopharmaceutical supply chain with particular strength in servicing the U.S. market. Telix’s goal is to establish a global supply chain with the capacity and reliability to support an increasing level of clinical activity through Telix-sponsored and investigator-led studies and to scale-up to commercial stage.”

Greg Piefer, SHINE founder and CEO added, “There continues to be a growing, critical need for more effective treatment of metastatic or late-stage cancers. Our exciting partnership with Telix allows us to bring hope to these patients as we continue to help deliver 177Lu for highly precise treatments that produce little damage in the tissue around treatment sites.” 

Telix has multiple therapeutic clinical trials underway using the medical radioisotope 177Lu. Its global supplier network includes a commercial supply agreement with ITM Isotope Technologies Munich SE (ITM), and clinical supply agreements with the Australian Nuclear Science and Technology Organisation (ANSTO), Eczacıbaşı-Monrol (Monrol), Eckert & Ziegler Strahlen- und Medizintechnik AG (EZAG) and SHINE Technologies.

To read the full media release please click here.

To return to Telix’s home page please click here.